



Contact: Daniel Burgin, T3 BioScience – [dburgin@t3biosci.com](mailto:dburgin@t3biosci.com)

***January 5, 2017***

### **T3 Bioscience and UWM begin advanced testing on potential new antibiotics**

MILWAUKEE – T3 BioScience LLC, a biotech start-up grown out of the University of Wisconsin-Milwaukee Research Foundation, will move into the advanced testing phase as part of their research into new antibiotics to treat so-called “superbugs” – bacteria that have become antibiotic resistant.

In January 2017, T3 Bioscience is scheduled to begin testing its Lead Compound for potential application as an antibiotic to treat *Pseudomonas aeruginosa*, a strain of bacteria that has proved resistant to other drug treatments and is one of the major causes of life-threatening, hospital-acquired infections, including pneumonia and bloodstream infections.

This research marks the next step in the partnerships between UWM and T3Bioscience LLC. The two companies have been focused on the identification of new bacteria through a proprietary screening method called PROMISA. A new bacterial strain found using PROMISA led to successful antibiotic testing on silkworms. It is these results, including data on pathogen sensitivity and the effectiveness of antibiotics, that led to the application to move forward to the next stage of the research.

“I am very pleased that after in-depth review of our efficacy and our safety protocols, the University has approved T3 Bioscience’s request to begin more advanced testing.” said Dr. Ching-Hong Yang, Chief Science Officer of T3 Bioscience. “Access to UWM’s newest bio-safety work space will allow T3 to safely handle pathogens under strict ethical and security guidelines.”

Rodney Swain, Dean of the College of Letters and Science noted, “The collaboration between T3 Bioscience and UWM is vital to the discovery of novel antibiotics that hopefully someday will become commercialized and save human lives. While this current test involves just *Pseudomonas aeruginosa*, T3 and UWM also are researching *Staphylococcus aureus* – the species from which the deadly MRSA infection arises.”

**About T3Bioscience:** T3Bioscience LLC specializes in developing new antibiotics for fighting gram-negative bacterial pathogens in both humans and agriculture. Research uses an internal proprietary methodology (PROMISA - Proprietary Methodology for Isolation of Antibiotic Bacteria) developed by Dr. Ching-Hong Yang over the last 15 years. Established in Milwaukee in 2013, the company's shareholders include the UWM Research Foundation and Duke Philanthropies. CEO Daniel Burgin joined in early 2016 complementing the research team with 25+ years of experience in business management. [www.t3biosci.com](http://www.t3biosci.com)

Read our Terminology Glossary at [www.t3biosci.com/t3glossary](http://www.t3biosci.com/t3glossary)

**About UWM:** Recognized as one of the nation's 115 top research universities, UW-Milwaukee provides a world-class education to 26,000 students from 81 countries. Its 14 schools and colleges include Wisconsin's only schools of architecture, freshwater sciences and public health, and it is a leading educator of nurses and teachers. UW-Milwaukee partners with leading companies to conduct joint research, offer student internships and serve as an economic engine for southeastern Wisconsin. The Princeton Review named UW-Milwaukee a 2017 "Best Midwestern" university based on overall academic excellence and student reviews, as well as a top "Green College."

##